ENPP1
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1
Also known as: ENPP1_HUMAN, M6S1, NPPS, PC-1, PCA1, PDNP1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P22413
- Gene
- ENPP1
- Ensembl
- ENSG00000197594
- Chromosome
- 6
- Canonical length
- 925 aa
- Protein class
- CD markers, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins
- Secretome location
- Secreted - unknown location
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene is a member of the ecto-nucleotide pyrophosphatase/phosphodiesterase (ENPP) family. The encoded protein is a type II transmembrane glycoprotein comprising two identical disulfide-bonded subunits. This protein has broad specificity and cleaves a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds of nucleotides and nucleotide sugars. This protein may function to hydrolyze nucleoside 5' triphosphates to their corresponding monophosphates and may also hydrolyze diadenosine polyphosphates. Mutations in this gene have been associated with 'idiopathic' infantile arterial calcification, ossification of the posterior longitudinal ligament of the spine (OPLL), and insulin resistance. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
925 residues, UniProt reviewed canonical sequence.
>P22413|ENPP1
1 MERDGCAGGG SRGGEGGRAP REGPAGNGRD RGRSHAAEAP GDPQAAASLL APMDVGEEPL
61 EKAARARTAK DPNTYKVLSL VLSVCVLTTI LGCIFGLKPS CAKEVKSCKG RCFERTFGNC
121 RCDAACVELG NCCLDYQETC IEPEHIWTCN KFRCGEKRLT RSLCACSDDC KDKGDCCINY
181 SSVCQGEKSW VEEPCESINE PQCPAGFETP PTLLFSLDGF RAEYLHTWGG LLPVISKLKK
241 CGTYTKNMRP VYPTKTFPNH YSIVTGLYPE SHGIIDNKMY DPKMNASFSL KSKEKFNPEW
301 YKGEPIWVTA KYQGLKSGTF FWPGSDVEIN GIFPDIYKMY NGSVPFEERI LAVLQWLQLP
361 KDERPHFYTL YLEEPDSSGH SYGPVSSEVI KALQRVDGMV GMLMDGLKEL NLHRCLNLIL
421 ISDHGMEQGS CKKYIYLNKY LGDVKNIKVI YGPAARLRPS DVPDKYYSFN YEGIARNLSC
481 REPNQHFKPY LKHFLPKRLH FAKSDRIEPL TFYLDPQWQL ALNPSERKYC GSGFHGSDNV
541 FSNMQALFVG YGPGFKHGIE ADTFENIEVY NLMCDLLNLT PAPNNGTHGS LNHLLKNPVY
601 TPKHPKEVHP LVQCPFTRNP RDNLGCSCNP SILPIEDFQT QFNLTVAEEK IIKHETLPYG
661 RPRVLQKENT ICLLSQHQFM SGYSQDILMP LWTSYTVDRN DSFSTEDFSN CLYQDFRIPL
721 SPVHKCSFYK NNTKVSYGFL SPPQLNKNSS GIYSEALLTT NIVPMYQSFQ VIWRYFHDTL
781 LRKYAEERNG VNVVSGPVFD FDYDGRCDSL ENLRQKRRVI RNQEILIPTH FFIVLTSCKD
841 TSQTPLHCEN LDTLAFILPH RTDNSESCVH GKHDSSWVEE LLMLHRARIT DVEHITGLSF
901 YQQRKEPVSD ILKLKTHLPT FSQEDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ENPP1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.26
- Highest tissue expression
- 41 nTPM
Expression across tissuesHPA
Tissue
- placenta: 41 nTPM
- liver: 29 nTPM
- pancreas: 27 nTPM
- parathyroid gland: 26 nTPM
- endometrium: 19 nTPM
- thyroid gland: 19 nTPM
Single-cell type
- lactotrophs: 426 nCPM
- somatotrophs: 291 nCPM
- hepatocytes: 217 nCPM
- endometrial stromal cells: 126 nCPM
- peritubular myoid cells: 121 nCPM
- medullary thymic epithelial cells: 110 nCPM
Immune cell
- NK-cell: 1.5 nTPM
- myeloid DC: 0.7 nTPM
- MAIT T-cell: 0.4 nTPM
- basophil: 0.3 nTPM
- naive B-cell: 0.1 nTPM
- neutrophil: 0.1 nTPM
Brain region
- midbrain: 3.4 nTPM
- medulla oblongata: 3.2 nTPM
- thalamus: 2.4 nTPM
- pons: 2.3 nTPM
- spinal cord: 2.2 nTPM
- white matter: 2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about ENPP1.
Disease | AllUniProt
Conditions ENPP1 is implicated in, by any mechanism.
- Ossification of the posterior longitudinal ligament of the spine (OPLL) MIM:602475
- Arterial calcification of infancy, generalized, 1 (GACI1) MIM:208000
- Type 2 diabetes mellitus (T2D) MIM:125853
- Hypophosphatemic rickets, autosomal recessive, 2 (ARHR2) MIM:613312
- Cole disease (COLED) MIM:615522
Disease | GeneticClinVar
100 pathogenic / likely-pathogenic of 935 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Arterial calcification, generalized, of infancy, 1
- Hypophosphatemic rickets, autosomal recessive, 2
- Hypopigmentation-punctate palmoplantar keratoderma syndrome
- Type 2 diabetes mellitus
- Inherited obesity
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.59
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.62
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- 3'-phosphoadenosine 5'-phosphosulfate metabolic process
- ATP metabolic process
- bone mineralization
- cellular response to insulin stimulus
- gene expression
- generation of precursor metabolites and energy
- immune response
- inorganic diphosphate transport
- intracellular phosphate ion homeostasis
- melanocyte differentiation
- negative regulation of bone mineralization
- negative regulation of cell growth
- negative regulation of D-glucose import
- negative regulation of fat cell differentiation
- negative regulation of glycogen biosynthetic process
- negative regulation of insulin receptor signaling pathway
- nucleic acid metabolic process
- nucleoside triphosphate catabolic process
- phosphate ion homeostasis
- phosphate-containing compound metabolic process
- regulation of bone mineralization
- response to ATP
- negative regulation of hh target transcription factor activity
Molecular functions
- 3',5'-cyclic-AMP phosphodiesterase activity
- 3'-phosphoadenosine 5'-phosphosulfate binding
- ATP binding
- ATP diphosphatase activity
- calcium ion binding
- cyclic-GMP-AMP hydrolase activity
- exonuclease activity
- GTP diphosphatase activity
- insulin receptor binding
- nucleic acid binding
- nucleoside triphosphate diphosphatase activity
- phosphatase activity
- phosphodiesterase I activity
- polysaccharide binding
- protein homodimerization activity
- scavenger receptor activity
- UTP diphosphatase activity
- zinc ion binding
- dinucleotide phosphatase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Somatomedin B domain
- DNA/RNA non-specific endonuclease/pyrophosphatase/phosphodiesterase domain
- Type I phosphodiesterase/nucleotide pyrophosphatase/phosphate transferase
- Alkaline-phosphatase-like, core domain superfamily
- Somatomedin B domain, chordata
- ENPP1-3/EXOG-like, endonuclease/phosphodiesterase domain
- Somatomedin B-like domain superfamily
- His-Me finger superfamily
- DNA/RNA non-specific endonuclease superfamily
- Somatomedin B domain
- DNA/RNA non-specific endonuclease
- Type I phosphodiesterase / nucleotide pyrophosphatase
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ENPP1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ENPP1 as an antibody target. Whether an autoantibody or antibody against ENPP1 could matter depends on whether native ENPP1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ENPP1 is annotated at the cell surface, where native ENPP1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label ENPP1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...